LONG-TERM DUAL ANTIPLATELET THERAPY WITH TICAGRELOR AFTER DRUG-ELUTING STENTS: RESULTS OF A DECISION ANALYTIC MODEL

The DAPT trial evaluated the role of longer-term dual antiplatelet therapy (DAPT) with either clopidogrel or prasugrel following percutaneous coronary intervention with drug-eluting stents (DES). However, ticagrelor has not been studied beyond 12 months of therapy. We sought to ascertain if there